The influence of microglia on the pathogenesis of Parkinson's disease

[1]  Marina A. Lynch,et al.  The Multifaceted Profile of Activated Microglia , 2009, Molecular Neurobiology.

[2]  A. Rodriguez-Perez,et al.  The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease , 2009, Journal of neurochemistry.

[3]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[4]  E. Carboni,et al.  PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s disease , 2009, The European journal of neuroscience.

[5]  Y. Suh,et al.  Minocycline and neurodegenerative diseases , 2009, Behavioural Brain Research.

[6]  E. Hirsch,et al.  Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.

[7]  Y. Nolan,et al.  Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: Implications for Parkinson’s disease , 2008, Behavioural Brain Research.

[8]  D. Chuang,et al.  Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. , 2008, The international journal of neuropsychopharmacology.

[9]  D. D. Di Monte,et al.  Macrophage Antigen Complex-1 Mediates Reactive Microgliosis and Progressive Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease1 , 2008, The Journal of Immunology.

[10]  Terina N. Martinez,et al.  Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Jau-Shyong Hong,et al.  Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. , 2008, Trends in immunology.

[12]  Xiaomin Su,et al.  Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  M. Beal,et al.  PPAR: a therapeutic target in Parkinson’s disease , 2008, Journal of neurochemistry.

[14]  P. Robinson.  Protein stability and aggregation in Parkinson's disease. , 2008, The Biochemical journal.

[15]  C. Ferrari,et al.  Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease , 2008, Brain : a journal of neurology.

[16]  Ninds Net-Pd Investigators.  A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results , 2008, Clinical neuropharmacology.

[17]  M. Hows,et al.  The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B , 2008, British journal of pharmacology.

[18]  E. Wolters,et al.  Variability in the clinical expression of Parkinson's disease , 2008, Journal of the Neurological Sciences.

[19]  P. Mcgeer,et al.  Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[20]  O. Isacson,et al.  Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease , 2008, Journal of Neuroinflammation.

[21]  Sufen Yang,et al.  Formyl-methionyl-leucyl-phenylalanine–Induced Dopaminergic Neurotoxicity via Microglial Activation: A Mediator between Peripheral Infection and Neurodegeneration? , 2008, Environmental health perspectives.

[22]  Y. Nolan,et al.  Neuroprotective effects of novel phosphatidylglycerol‐based phospholipids in the 6‐hydroxydopamine model of Parkinson's disease , 2008, The European journal of neuroscience.

[23]  F. Rossi,et al.  Local self-renewal can sustain CNS microglia maintenance and function throughout adult life , 2007, Nature Neuroscience.

[24]  M. Block,et al.  Chronic microglial activation and progressive dopaminergic neurotoxicity. , 2007, Biochemical Society transactions.

[25]  M. Tansey,et al.  Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.

[26]  P. Gean,et al.  Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity , 2007, Neuroscience.

[27]  M. Lynch,et al.  CD200 Ligand–Receptor Interaction Modulates Microglial Activation In Vivo and In Vitro: A Role for IL-4 , 2007, The Journal of Neuroscience.

[28]  C. Adler,et al.  Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits , 2007, Acta Neuropathologica.

[29]  E. Esposito,et al.  Non-steroidal anti-inflammatory drugs in Parkinson's disease , 2007, Experimental Neurology.

[30]  G. Bing,et al.  Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra , 2007, Neurobiology of Aging.

[31]  F. Crews,et al.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration , 2007, Glia.

[32]  G. Bing,et al.  Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system , 2007, Journal of neurochemistry.

[33]  Colm Cunningham,et al.  Systemic infections and inflammation affect chronic neurodegeneration , 2007, Nature Reviews Immunology.

[34]  L. Moran,et al.  The medial and lateral substantia nigra in Parkinson’s disease: mRNA profiles associated with higher brain tissue vulnerability , 2007, Neurogenetics.

[35]  S. Lorenzl,et al.  A pivotal role of matrix metalloproteinase‐3 activity in dopaminergic neuronal degeneration via microglial activation , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  P. Gean,et al.  Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes , 2006, Molecular Psychiatry.

[37]  M. Lynch,et al.  The age‐related attenuation in long‐term potentiation is associated with microglial activation , 2006, Journal of neurochemistry.

[38]  C. Ferrari,et al.  Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra , 2006, Neurobiology of Disease.

[39]  B. Botterman,et al.  Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.

[40]  B. Liu.  Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson’s disease , 2006, The AAPS Journal.

[41]  W. Kukull,et al.  Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[42]  E. Esposito,et al.  Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: An in vivo microdialysis study , 2006, Brain Research.

[43]  A. Granholm,et al.  Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease , 2006, Brain Research.

[44]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[45]  M. Dragunow,et al.  Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide , 2006, Brain Research.

[46]  T. Möller,et al.  Microglia Biology in Health and Disease , 2006, Journal of Neuroimmune Pharmacology.

[47]  V. Perry,et al.  Central and Systemic Endotoxin Challenges Exacerbate the Local Inflammatory Response and Increase Neuronal Death during Chronic Neurodegeneration , 2005, The Journal of Neuroscience.

[48]  J. Antel,et al.  TLR Signaling Tailors Innate Immune Responses in Human Microglia and Astrocytes1 , 2005, The Journal of Immunology.

[49]  J. Watters,et al.  Purinergic receptor modulation of BV-2 microglial cell activity: Potential involvement of p38 MAP kinase and CREB , 2005, Journal of Neuroimmunology.

[50]  J. de Vellis,et al.  Microglia in health and disease , 2005, Journal of neuroscience research.

[51]  W. Gan,et al.  ATP mediates rapid microglial response to local brain injury in vivo , 2005, Nature Neuroscience.

[52]  F. Helmchen,et al.  Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.

[53]  R. Gregersen,et al.  Proliferating resident microglia express the stem cell antigen CD34 in response to acute neural injury , 2005, Glia.

[54]  T. Joh,et al.  Matrix Metalloproteinase-3: A Novel Signaling Proteinase from Apoptotic Neuronal Cells That Activates Microglia , 2005, The Journal of Neuroscience.

[55]  M. Wirenfeldt,et al.  Microglial cell population dynamics in the injured adult central nervous system , 2005, Brain Research Reviews.

[56]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  D. Chuang,et al.  Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. , 2005, Brain research. Molecular brain research.

[58]  M. Lynch,et al.  Role of Interleukin-4 in Regulation of Age-related Inflammatory Changes in the Hippocampus* , 2005, Journal of Biological Chemistry.

[59]  A. Floden,et al.  β-Amyloid-Stimulated Microglia Induce Neuron Death via Synergistic Stimulation of Tumor Necrosis Factor α and NMDA Receptors , 2005, The Journal of Neuroscience.

[60]  E. Ongini,et al.  Nuclear receptor peroxisome proliferator‐activated receptor‐γ is activated in rat microglial cells by the anti‐inflammatory drug HCT1026, a derivative of flurbiprofen , 2005, Journal of neurochemistry.

[61]  P. Carvey,et al.  Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain , 2004, Neuroscience.

[62]  P. Mcgeer,et al.  Inflammation and the Degenerative Diseases of Aging , 2004, Annals of the New York Academy of Sciences.

[63]  A. Członkowska,et al.  Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. , 2004, International immunopharmacology.

[64]  V. Perry.  The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease , 2004, Brain, Behavior, and Immunity.

[65]  E. Bézard,et al.  Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease , 2004, The European journal of neuroscience.

[66]  J. Cano,et al.  Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system , 2004, Neurobiology of Disease.

[67]  J. Dichgans,et al.  Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation , 2003 .

[68]  Andre Parent,et al.  Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.

[69]  C. Ferrari,et al.  Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease , 2003, The European journal of neuroscience.

[70]  S. Lorenzl,et al.  Minocycline enhances MPTP toxicity to dopaminergic neurons , 2003, Journal of neuroscience research.

[71]  Makoto Sawada,et al.  Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.

[72]  Bin Liu,et al.  Critical role of microglial NADPH oxidase‐derived free radicals in the in vitro MPTP model of Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  M. Vila,et al.  The 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mouse Model , 2003 .

[74]  S. Fahn.  Description of Parkinson's Disease as a Clinical Syndrome , 2003, Annals of the New York Academy of Sciences.

[75]  M. Vila,et al.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Nussbaum,et al.  Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.

[77]  M. Emre.  Dementia associated with Parkinson's disease , 2003, The Lancet Neurology.

[78]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[79]  G. Deuschl,et al.  Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  G. Halliday,et al.  An inflammatory review of Parkinson’s disease , 2002, Progress in Neurobiology.

[81]  U. Hanisch,et al.  Microglia as a source and target of cytokines , 2002, Glia.

[82]  Rena Li,et al.  Microglia and inflammatory mechanisms in the clearance of amyloid β peptide , 2002 .

[83]  G. Donnan,et al.  Macrophages and Microglia Produce Local Trophic Gradients That Stimulate Axonal Sprouting Toward but Not beyond the Wound Edge , 2002, Molecular and Cellular Neuroscience.

[84]  G. Winocur,et al.  Brain Interleukin-1 Is Involved in Spatial Memory and Passive Avoidance Conditioning , 2002, Neurobiology of Learning and Memory.

[85]  A. Członkowska,et al.  Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. , 2002, International immunopharmacology.

[86]  A. Barclay,et al.  CD200 and membrane protein interactions in the control of myeloid cells. , 2002, Trends in immunology.

[87]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[88]  J. Cano,et al.  The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐α, IL‐1β and IFN‐γ , 2002 .

[89]  R. Dantzer,et al.  Cytokine-induced sickness behaviour: mechanisms and implications , 2002, Trends in Neurosciences.

[90]  P. Andrade-Gordon,et al.  Participation of protease‐activated receptor‐1 in thrombin‐induced microglial activation , 2002, Journal of neurochemistry.

[91]  P. Carvey,et al.  Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide , 2002 .

[92]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[93]  W. Le,et al.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.

[94]  J. Koistinaho,et al.  Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia1 , 2001, The Journal of Immunology.

[95]  P. Ricciardi-Castagnoli,et al.  Developmental plasticity of CNS microglia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[96]  B. Fiebich,et al.  Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.

[97]  A. Compston,et al.  Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors , 2001, Journal of Neuroimmunology.

[98]  G. Wilkin,et al.  Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2 , 2000, Molecular and Cellular Neuroscience.

[99]  B. Blom,et al.  Down-regulation of the macrophage lineage through interaction with OX2 (CD200). , 2000, Science.

[100]  S. Yang,et al.  Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. , 2000, The Journal of pharmacology and experimental therapeutics.

[101]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[102]  R. Mohney,et al.  Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.

[103]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[104]  K. Mohanakumar,et al.  Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 2000, Brain Research.

[105]  Bin Liu,et al.  Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron–glia co-cultures , 2000, Neuroscience.

[106]  G. Bing,et al.  Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats , 2000, Neuroscience.

[107]  Jau-Shyong Hong,et al.  Influence of neurons on lipopolysaccharide-stimulated production of nitric oxide and tumor necrosis factor-α by cultured glia , 2000, Brain Research.

[108]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[109]  R. Nitsch,et al.  Morphological, immunophenotypical and electrophysiological properties of resting microglia in vitro , 1999, The European journal of neuroscience.

[110]  Raj Kumar Gupta,et al.  Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. , 1999, Neurology.

[111]  R. Dobbs,et al.  Association of circulating TNF‐α and IL‐6 with ageing and parkinsonism , 1999 .

[112]  Geoffrey A. Donnan,et al.  Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor , 1999, The Journal of Neuroscience.

[113]  A. Członkowska,et al.  The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.

[114]  B. Babior.  NADPH oxidase: an update. , 1999, Blood.

[115]  M. Sakanaka,et al.  Induction of resting microglia in culture medium devoid of glycine and serine , 1998, Glia.

[116]  C. Carter,et al.  Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.

[117]  V. Perry.  A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation , 1998, Journal of Neuroimmunology.

[118]  M. A. Cuadros,et al.  The origin and differentiation of microglial cells during development , 1998, Progress in Neurobiology.

[119]  J. Cano,et al.  Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System , 1998, Journal of neurochemistry.

[120]  S. Daniel,et al.  Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[121]  J. Loike,et al.  Microglia, Scavenger Receptors, and the Pathogenesis of Alzheimer’s Disease , 1998, Neurobiology of Aging.

[122]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[123]  M. Memo,et al.  Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-κB Activation , 1996, Science.

[124]  G. Kreutzberg.  Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[125]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[126]  I. Black,et al.  Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[127]  M. Pawlikowski,et al.  Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease. , 1996, Neuroimmunomodulation.

[128]  H. Soininen,et al.  Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia , 1996, Neurology.

[129]  I. Pérez-Otaño,et al.  Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures , 1995, Brain Research.

[130]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[131]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[132]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[133]  H. Anisman,et al.  Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6 , 1994, Brain Research.

[134]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[135]  H. Saito,et al.  Microglial conditioned medium promotes survival and development of cultured mesencephalic neurons from embryonic rat brain , 1993, Journal of neuroscience research.

[136]  T. Molitor,et al.  Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. , 1992, Journal of immunology.

[137]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[138]  S. Gordon,et al.  Macrophages in haemopoietic and other tissues of the developing mouse detected by the monoclonal antibody F4/80. , 1991, Development.

[139]  K. Ashwell,et al.  Microglia and cell death in the developing mouse cerebellum. , 1990, Brain research. Developmental brain research.

[140]  P. Mcgeer,et al.  Microglial response to 6-hydroxydopamine-induced substantia nigra lesions , 1989, Brain Research.

[141]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[142]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[143]  W. Hickey,et al.  Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. , 1988, Science.

[144]  W. Poewe,et al.  THE CENTENARY OF FRIEDERICH H. LEWY 1885–1950 , 1986, Neuropathology and applied neurobiology.

[145]  Langston Jw,et al.  Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983 .

[146]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[147]  M. Swash,et al.  Post-encephalitic Parkinsonism: current experience , 1981, Journal of neurology, neurosurgery, and psychiatry.

[148]  J. Parkinson.  AN ESSAY ON THE SHAKING PALSY , 1969 .

[149]  W. Penfield.  Cytology & cellular pathology of the nervous system , 1965 .

[150]  R. Peixoto,et al.  Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway , 2008, Journal of Neuroinflammation.

[151]  R. Doty.  Olfaction in Parkinson's disease. , 2007, Parkinsonism & related disorders.

[152]  M. Sawada,et al.  Role of cytokines in inflammatory process in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[153]  Jau-Shyong Hong,et al.  Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10. , 2006, Journal of neural transmission. Supplementum.

[154]  A. Brownell,et al.  Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease , 2004 .

[155]  P. Carvey,et al.  In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain , 2002, Movement disorders : official journal of the Movement Disorder Society.

[156]  H. Ichinose,et al.  Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain , 2000, Journal of Neural Transmission.

[157]  H. Anisman,et al.  Anhedonic and anxiogenic effects of cytokine exposure. , 1999, Advances in experimental medicine and biology.

[158]  W. Hall,et al.  A rat model of Parkinson's disease induced by Japanese encephalitis virus. , 1997, Journal of neurovirology.

[159]  H. Braak,et al.  Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[160]  C. Marsden,et al.  Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease , 1992, Annals of neurology.

[161]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .